The article discusses Sam Altman, the CEO of OpenAI, and his interests beyond generative AI. It highlights his investments in various ventures, including nuclear energy, biotech, and longevity research. Altman has also been building a portfolio of companies that focus on long-term sustainability and human enhancement.
Altman's shift towards nuclear energy is notable, as he has called past bans on nuclear energy over safety concerns "incredibly dumb." He has financially backed the nuclear energy startup Helion, which aims to build a nuclear fusion power plant to fuel Microsoft's data centers. Altman also served as chair of the board for Oklo, a nuclear energy startup that was acquired by General Electric.
In biotech, Altman has invested in Retro Biosciences, a longevity startup that aims to develop an anti-aging pill using psilocybin. He has also co-founded Merge Labs, a rival to Neuralink's brain implant technology, which aims to develop AI-powered neural interfaces. Altman has expressed interest in exploring the possibilities of neural interfaces and their potential to enhance human cognition.
Altman's interests extend beyond technology to include philosophical and spiritual pursuits. He has meditated with mindfulness author Jack Kornfield and explored the concept of consciousness with him. Kornfield suggested that Altman might be able to answer questions about AI consciousness by taking psilocybin and observing the effects on servers.
Overall, the article suggests that Sam Altman is a visionary who sees technology as a means to achieve long-term sustainability and human enhancement. His investments and ventures reflect his interests in nuclear energy, biotech, and longevity research, as well as his exploration of the philosophical and spiritual implications of AI and consciousness.
Altman's shift towards nuclear energy is notable, as he has called past bans on nuclear energy over safety concerns "incredibly dumb." He has financially backed the nuclear energy startup Helion, which aims to build a nuclear fusion power plant to fuel Microsoft's data centers. Altman also served as chair of the board for Oklo, a nuclear energy startup that was acquired by General Electric.
In biotech, Altman has invested in Retro Biosciences, a longevity startup that aims to develop an anti-aging pill using psilocybin. He has also co-founded Merge Labs, a rival to Neuralink's brain implant technology, which aims to develop AI-powered neural interfaces. Altman has expressed interest in exploring the possibilities of neural interfaces and their potential to enhance human cognition.
Altman's interests extend beyond technology to include philosophical and spiritual pursuits. He has meditated with mindfulness author Jack Kornfield and explored the concept of consciousness with him. Kornfield suggested that Altman might be able to answer questions about AI consciousness by taking psilocybin and observing the effects on servers.
Overall, the article suggests that Sam Altman is a visionary who sees technology as a means to achieve long-term sustainability and human enhancement. His investments and ventures reflect his interests in nuclear energy, biotech, and longevity research, as well as his exploration of the philosophical and spiritual implications of AI and consciousness.